Needham Maintains Buy on Cormedix, Lowers Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Serge Belanger has maintained a 'Buy' rating on Cormedix (NASDAQ:CRMD) but lowered the price target from $13 to $12.

August 08, 2023 | 5:45 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Needham analyst has maintained a 'Buy' rating on Cormedix but lowered the price target from $13 to $12.
The news is directly related to Cormedix and is likely to influence investor sentiment. While the 'Buy' rating is maintained, the lowering of the price target might create some uncertainty among investors, potentially impacting the stock's short-term performance.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100